How is symptom flare defined in musculoskeletal conditions: a systematic review by Costa, Nathalia et al.
Author’s Accepted Manuscript
How is symptom flare defined in musculoskeletal
conditions: A systematic review
Nathalia K. Costa, Manuela L. Ferreira, Marita Cross,
Joanna Makovey, Paul W. Hodges
PII: S0049-0172(17)30570-X
DOI: https://doi.org/10.1016/j.semarthrit.2018.01.012
Reference: YSARH51303
To appear in: Seminars in Arthritis and Rheumatism
Cite this article as: Nathalia K. Costa, Manuela L. Ferreira, Marita Cross,
Joanna Makovey and Paul W. Hodges, How is symptom flare defined in
musculoskeletal conditions: A systematic review, Seminars in Arthritis and
Rheumatism,doi:10.1016/j.semarthrit.2018.01.012
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version
of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable
form. Please note that during the production process errors may be discovered
which could affect the content, and all legal disclaimers that apply to the
journal pertain.
image
www.elsevier.com/locate/bios
 Title: How is symptom flare defined in musculoskeletal conditions: A systematic review 
 
Authors: Nathalia K. Costa, BPhty
a
; Manuela L. Ferreira, PhD
b
; Marita Cross, PhD
b
; Joanna 
Makovey, PhD
b
, Paul W. Hodges, PhD
a 
 
Affiliations: 
a 
The University of Queensland, School of Health and Rehabilitation Sciences, 
Brisbane, QLD, Australia; 
b
 The University of Sydney, Institute of Bone and Joint Research, 
The Kolling Institute, Sydney Medical School 
 
Source of support: This study is supported by a Program grant (APP1091302); Centre of 
Research Excellence grant (APP1079078) and Fellowship (PH – APP1102905) from the 
National Health and Medical Research Council (NHMRC) of Australia. MLF is supported by 
the Sydney Medical School Foundation Fellowship, Sydney Medical School/The University 
of Sydney. 
Disclaimers: The authors have no conflicts of interest to declare. 
Corresponding author: 
Dr Paul Hodges 
Centre of Clinical Research Excellence in Spinal Pain, Injury and Health, School of Health 
and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, 4072 
Australia  
E-mail: p.hodges@uq.edu.au 
Tel: +61 404 854 589 
 Abstract  
Objective: To systematically review the definitions for “flare” in musculoskeletal conditions, 
the derivation processes, and validation of definitions for the 12 most burdensome 
musculoskeletal conditions.  
Methods: A literature search was conducted in MEDLINE, EMBASE, CINAHL, AMED, 
PsycInfo and Lilacs to identify studies that investigated derivation or validation of a flare 
definition, which we considered as a phrase or group of domains.  
Results: Reports of derivation of flare definitions were identified for 9/12 musculoskeletal 
conditions. Validation of flare definitions was initiated for 4/12. For each condition, different 
derivation and validation methods have been used, with variable levels of consumer 
involvement, and in some cases different groups have worked on the process in parallel. 
Although some flare definitions began simply as “symptom worsening” or “change in 
treatment”, most evolved into multidimensional definitions that include: pain, impact on 
function, joint symptoms, and emotional elements. Frequently initial attempts to create phrase 
to define the term flare evolved into consensus on the breadth of domains involved. 
Validation has compared flare definitions/domains against measures of disease activity, 
clinicians’ diagnosis, response to drug therapy, or a combination.  
Conclusion: This review suggests that greater characterisation and definition of flares in 
musculoskeletal conditions are linked to the inclusion of multiple perspectives, multifaceted 
domains and compound comparators for their validation. Further work is required to optimise 
and test the derived definitions for most musculoskeletal conditions. As some elements are 
disease-specific flare definitions cannot be extrapolated to other conditions. Research 
regarding flare in back pain (most burdensome disease) is limited. 
Keywords: Systematic review, flare, definition, musculoskeletal diseases. 
 1. Introduction  
Musculoskeletal conditions are pervasive and a leading contributor to the global 
burden of disease (1). As many musculoskeletal conditions do not have a cure and become 
lifelong problems, research has focussed on identification of factors that influence the 
progression from acute to chronic conditions, the determinants of the rate of progression of 
the disease, and possible clinical or environmental interventions to halt the progression or to 
reduce the impact of disease. Such consideration depends on a clear understanding of the 
time-course of disease and this relies on clear and unambiguous measures of disease state. A 
major issue is that although symptoms are ongoing, most are characterised by variation or 
fluctuation of symptoms (2) but not all fluctuations are likely to be important (3, 4). For 
several conditions, periods of increased severity of the condition are referred to as a “flare” or 
“flare-up”. Despite the frequent use of this term in research and clinical practice, it is rarely 
clearly defined. It is difficult to be certain whether a flare has the same meaning for different 
conditions. Furthermore, it is unclear whether the terms are used consistently between 
patients, clinicians and researchers, or within these groups.  
For some conditions, such as rheumatoid arthritis (RA), a detailed process has been 
initiated to define and understand flare (5, 6). In these cases, there is advanced understanding 
of patient and clinician interpretations of the term, but the results of each step in the process 
are published in individual papers (e.g. (7, 8)) making it difficult to clarify the overall 
derivation process. For other conditions, parts of the process of derivation of a definition has 
been undertaken, but without overarching coordination of the process. Consequently, the term 
flare is used for multiple purposes such as an outcome measure for clinical trials without an 
explicit definition in most cases. To fully ascertain the current understanding of flare and its 
use in research and clinical practice it was necessary to undertake a systematic review of the 
literature.  
  The overall aim of this systematic review was to comprehensively review the 
definitions that have been derived and validated for the term flare (or flare up) in the 12 most 
burdensome musculoskeletal conditions defined in the Global Burden of Disease Study (9, 
10). Our interest was to gain a comprehensive understanding of flare definitions and domains 
used to define a flare (i.e. worsening of condition; change in treatment). Our specific aims 
were to: (i) document and contrast the definitions or domains used to identify and/or 
characterise flare for the most burdensome musculoskeletal conditions; (ii) assess the 
methods used to derive the definitions or domains; and (iii) review studies that assess the 
validity of definitions or domains of flare. 
 
2. Methods  
2.1 Search strategy 
The methods of this review have been registered with PROSPERO 
(CRD42017056996). We performed a systematic search to identify studies of the key 
musculoskeletal conditions that derived or validated a definition for flare. The key 
musculoskeletal conditions considered were the “major” and “other musculoskeletal 
conditions” determined by Global Burden of Disease (GBD) 2010 Study (10, 11). The “major 
musculoskeletal conditions” are the ones more likely to contribute to the largest proportion of 
musculoskeletal burden based on daily-adjusted life year, i.e., hip and/or knee osteoarthritis 
(OA), low back pain (LBP), rheumatoid arthritis (RA), gout and neck pain. The group of 
“other musculoskeletal disorders” includes systemic lupus erythematosus (SLE), ankylosing 
spondylitis (AS), psoriatic arthritis (PsA), juvenile rheumatoid arthritis (jRA), osteomyelitis, 
fibromyalgia and shoulder pain. We used the search term “flare” combined with each of those 
conditions. A systematic search was conducted in MEDLINE, EMBASE CINAHL, AMED, 
 PsycInfo and Lilacs from the earliest record to February 2017. Searches were conducted in 2 
phases; December 2015 and February 2017. The search terms were adapted for use according 
to database-specific filters. No restriction was applied on study design or language.  
2.2 Study selection 
The results were exported into an EndNote X7.0 database, and duplicates were 
removed. Studies on animals, pregnant women, participants with non-musculoskeletal 
conditions (e.g. cancer) or undergoing surgery were excluded. Two independent reviewers 
(NC and MF) screened all titles and abstracts for potential inclusion. Disagreement was 
resolved by discussion. Full texts of all potentially eligible studies were evaluated for 
inclusion by two reviewers (NC and PH) on the probability that (1) the study defined flare, or 
(2) attempted to validate flare definitions or domains. To capture studies which defined flare, 
we considered the term “defined” to broadly mean both a “phrase” that provided a formal 
definition of the state of flare or a multi-dimensional tool/group of “domains” that could be 
considered to determine whether or not a person was experiencing a flare. Studies including 
mixed patient populations (e.g. non-musculoskeletal conditions and musculoskeletal 
conditions) and patient populations with non-musculoskeletal symptoms (e.g. skin features in 
psoriatic arthritis) were only included if the flare data were separately presented for 
musculoskeletal conditions. Studies written in languages other than English were eligible if a 
translator was available. However, no eligible study was found in non-English languages. 
Studies including induced flares were excluded.  
2.3 Study grouping 
Identified studies were grouped according to the following purposes:  
 GROUP A: Studies that described an experimental study or series of studies that 
aimed to derive a definition or set of domains that characterise a flare; 
  GROUP B: Studies that aimed test the validity of a definition that had been 
proposed/derived for flare or a set of domains that characterise flare. 
2.4 Assessment of study methodological quality 
Study methodological quality was assessed as it pertains to the purpose of our review 
(derivation and validation of the definition for flare) and not the principal design of the study 
(e.g. if data from an RCT was included, the design of the RCT was not evaluated, but the 
process related to derivation of the definition of flare was considered). Different aspects of 
study quality were considered for each study group.  
A major consideration for papers in Group A was that for most conditions, the entire 
process used for derivation of a definition was not contained within a single paper, but 
instead described in a series of papers. The methodological quality was appraised in terms of 
whether the process: 
- Provided clear identification of disease or condition; 
- Considered the perspective of patients, clinicians, and/or researchers (groups were 
recorded); 
- Involved an experimental method to derive the definition (recorded as Delphi; 
qualitative study; consensus meeting; etc.); 
- Considered single or multiple domains to define flare (domains were recorded); 
- Used an experimental method to identify a threshold/cut-off score on a symptom scale 
to characterise a flare (if a cut-off was used this was recorded as “yes” or “arbitrary” 
cut-off); 
- Involved a method to reach consensus for the definition/domains (recorded as yes/no). 
 Methodological quality of studies in Group B was appraised using the following 
criteria: 
 - Clear identification of disease or condition; 
- Representativeness of the sample (i.e. sampled from general community, or sampled 
from a specific group of patients);   
- Clear description of comparator (comparator recorded); 
- Blinding of patients and investigators to assessment of comparators used to validate a 
proposed definition (recorded as yes/no/not applicable);   
- Inclusion of follow-up long enough to allow for flares to be experienced (recorded as 
yes/no/not applicable).  
2. 5 Data extraction  
The data extracted from the studies differed according to group. For all studies we 
recorded the authors, year of publication and condition studied. For studies in Group A we 
recorded the methods used to derive and/or definition or domains, the contributing groups 
(i.e. consumers, clinicians), whether consensus for the definition/domains was achieved, the 
flare definition or identified domains, and measurement tools when appropriate. All 
definitions or groups of domains used to characterise flares included reference to multiple 
features, and the terms used to describe these differed between diseases and research groups. 
To assist with comparison of the definitions/domains, we undertook a thematic analysis and 
allocated each key elements or features of the definitions to one of eleven themes identified 
by consensus of the author group (Table 1). 
For studies in Group B we documented the definition and/or domains of a flare, the 
methods used to test its validity, the groups involved in the validation process, whether the 
definition/domains were validated, and the comparator used for the validation of the 
definition. Data extraction was conducted by independently by reviewers (NC, PH and MF) 
and in case of disagreement, consensus was reached by discussion.  
 2.6 Data presentation 
Data on derivation and validation processes are presented separately for each 
musculoskeletal condition in Table 2 and 3. Study details and assessment of study quality for 
Groups A and B are presented separately in Tables 4 and 5, respectively.  
 
3. Results  
Figure 1 presents the flow chart of the papers screened and included in this review. 
Data are presented according to the two a priori defined categories below.  
3.1 GROUP A: Derivation of a definition or domains of flare.  
 Twenty-eight studies described the derivation of a definition of flare or described the 
identification of domains that characterise a flare. Most considered rheumatologic conditions 
(RA – 9; jRA – 1; Gout – 3; SLE – 6; Juvenile SLE – 1; PsA – 2; OA – 1; AS – 3; 
Fibromyalgia - 1) and one study derived a definition for flare in LBP. Diverse methods have 
been used to develop definitions. All studies clearly identified the condition and included an 
experimental method in their derivation, and the derived definition included at least two 
domains. Forty-six per cent of studies included perspectives from more than one interest 
group. Forty-three per cent involved a method to reach consensus for the definition/domains. 
Only 21% of studies used an experimental method to identify the cut-off on a symptom scale. 
Figure 2 shows the number of conditions that include consideration of each of the themes in 
the definition. The themes of the most commonly included domains were “pain”, “impact on 
function” and “joint symptoms”. Figure 3 shows the number of themes considered for each 
condition. RA, SLE and AS consider the broadest range of themes in their definition. The 
process undertaken, the methodological quality and the resulting definition or domains 
differed between conditions and are presented below separately by condition. 
 Rheumatoid Arthritis (RA) 
The Outcome Measures in Rheumatology (OMERACT) initiative has coordinated 
the derivation of a definition of flare in RA, published across nine papers and one abstract 
(four papers considered validation, see Group B). An initial working definition was derived at 
the 9th OMERACT meeting in 2008 (OMERACT9) and focused on the domains “worsening 
of condition”, “duration”, “symptom intensity”, “change in treatment” (5-7). Analyses of 
focus groups of patients in 5 countries showed that global visual analogue scale (VAS) and 
joint count do not adequately capture flares, suggesting a need for a deeper understanding of 
this experience (12). More recent publications describe a change in strategy from a phrase to 
define flare, to the identification of multiple domains of disease activity (8) that form the 
foundation for a questionnaire to indicate the presence of a flare. The Preliminary Flare 
Questionnaire (PFQ) was developed in 2012 at OMERACT11 (13)  and using core flare 
domains identified in previous meetings. There was lack of consensus between views of 
consumers and clinicians regarding flare domains (e.g. patients, but not, clinicians considered 
fatigue to be important). Validation of the Rheumatoid Arthritis Flare Core Domain Set and 
the Preliminary Flare Questionnaire (PFQ) are discussed in Group B.  
 In parallel, the Strategy of Treatment in Patients with Rheumatoid Arthritis group of 
the French Society of Rheumatology derived a definition of RA flare through the 
development of a self-administered questionnaire (FLARE-RA) containing multiple partially 
distinct domains (14, 15). The FLARE-RA has been validated (see Group B) and a threshold 
of 2.5 is suggested for identification of RA flare (16).  
 
 
 
 Juvenile Rheumatoid Arthritis (JRA) 
 Brunner et al. (17) used data from a randomised controlled trial of a disease-
modifying drug (Etanercept) to propose and assess candidate flare definitions. Participants in 
the placebo group were assumed to experience flares during the trial duration, whereas those 
in the treatment arm were assumed to be free from flare. The combination of scores from a 
group of clinical variables (core response variables; CRV) was tested using receiver operator 
characteristic (ROC) and positive and negative predictive values for group allocation. Three 
proposed definitions performed adequately for accurate identification of presence of a flare. 
These related to the domain of “worsening of condition” as assessed by clinical tests, in 
combination with results from questionnaires and laboratory tests. 
Gout  
 Although flare is frequently identified as an important feature of chronic gout (18-20) 
there have be few attempts to define or identify the domains that characterise a gout flare. A 
consensus exercise involving two Delphi surveys and a cognitive mapping process involving 
patients, clinicians and experts identified nine key elements of a gout flare definition (21). 
The European League Against Rheumatism (EULAR) evaluated the utility of these elements 
of gout flare to develop a patient-centred definition. At eight international sites, 210 patients 
were assessed by nine experienced rheumatologists. The physician’s determination of the 
presence or absence of gout flare was the comparator. Logistic regression and classification 
and regression tree (CART) were used to identify the best predictors of a flare. Patient-
reported flare, presence of any warm joints or swollen joints, and joint pain at rest with a 
score >3 were strongly associated with the comparator physician’s determination of presence 
of a gout flare (22). 
  A novel approach to flare definition was attempted by MacFarlane et al (23). Using 
computerised medical records, they aimed to identify claims-based algorithms that could to 
identify gout flares and assessed against physician documentation of gout flare. Claims-based 
algorithms did not accurately identify gout flares.  
Systemic Lupus Erythematosus (SLE)  
 Flares have been largely recognised as an important feature of the disease pattern in 
SLE and used to represent “worsening of disease activity” (24). Eight instruments in different 
versions and modifications (e.g. British Isles Lupus Assessment Group 2004 index – BILAG, 
Systemic Lupus Erythematosus Disease Activity Index – SLEDAI, The Safety of Estrogen in 
Lupus Erythematosus National Assessment – SELENA, Lupus Activity Index - LAI) have 
been proposed. As SLE involves many systems other than the musculoskeletal system, most 
definitions include a multi-system perspective (e.g. seizure, cardiorespiratory symptoms, etc). 
Most research has used a change in score on these disease activity instruments to quantify 
and characterize flare (24). Cut-offs for a flare were established for BILAG, SLEDAI, 
SELENA SLEDAI and LAI (25-29).  
 In 2006, The Lupus Foundation of America (LFA) convened an International 
Consensus Panel “Definition and Validation of Lupus Flares” to evaluate needs in defining 
and measuring SLE flares. Two web-based Delphi surveys of physicians, a second consensus 
conference (which included patients), and a third Delphi survey were undertaken to reach 
final consensus (30). The definition of flare was broadened to include more domains as a 
result of this process. A separate study achieved a consensus for a flare definition and 
candidate flare criteria in Juvenile Systemic Lupus Erythematosus (jSLE) (31). Work to 
assess validity of definitions and instruments has been done (see Group B).  
 
 Psoriatic arthritis (PsA)   
          Moverley et al. (32) aimed to define flare in PsA. Interview data from patients were 
analysed thematically. Flares were defined as a collection of interacting “physical”, 
“psychological” and “emotional” symptoms defined by several domains. Furthering this 
work, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 
conducted two Delphi surveys and a face-to-face discussion to define flare and its domains 
towards the development of a questionnaire to identify flare in PsA (33). Development of the 
questionnaire is ongoing.   
Osteoarthritis (OA) 
 Marty et al. (34) conducted two observational cross-sectional studies to derive and 
validate a diagnostic score for OA flare based on clinical and radiological features. Initial 
data were obtained from general practitioners and used to develop a diagnostic score for 
patients seeking primary care. To build the instrument and derive cut-off scores, patients with 
stable condition and those experiencing a flare were recruited. Patients’ demographics and 
clinical characteristics, including pain severity, functional impairment and treatment, were 
included in logistic regression models to identify factors independently associated with flare. 
A score ≥7 was identified when each factor was given a weight for the odds of not having a 
flare. This score was validated using a rheumatologist database (see Group B). 
Ankylosing Spondylitis (AS) 
 Brophy et al. (35) examined patients’ perceptions of the important domains for flare 
definition in AS. In twenty group meetings of 7-12 participants, 214 patients were asked 
questions regarding flare and its triggers, duration, sequelae and frequency. A consensus 
definition of flare was obtained by each group. Data revealed two forms of flares (“localised 
 to one area” and “throughout the body”). Both were marked by highly painful symptoms 
triggered by stress in the majority of cases.  
 The Assessment of Spondyloarthritis (ASAS) group conducted a systematic review of 
flare definitions and vignette exercises to develop a consensus definition of flare. Diverse 
flare definitions were found and 12 preliminary draft flare definitions were proposed for 
further validation (36).  
 Godfrin-Valnet et al. (37) aimed to derive a definition of flare based on disease 
activity indices. ROC curves were used to identify thresholds for optimum sensitivity and 
specificity to detect flares reported by patients and physicians. Specificity was strong, but 
sensitivity was only moderate and agreement between patients and physicians was only 
moderate (Kappa 0.68). 
Fibromyalgia 
 Vincent et al. (38) identified domains of flares in patients with fibromyalgia using a 
qualitative survey. Content analysis identified three main content areas and key themes 
within each of these content areas: causes of flares (stress, overdoing, poor sleep and weather 
changes), flare symptoms (flu-like symptoms, pain, fatigue, other symptoms) and dealing 
with flares (treatments, rest, avoid everything and wait it out). No definition was derived or 
validation attempted. 
Low Back Pain  
One study has proposed a definition of flare for LBP (39). This qualitative study 
originally aimed to examine how individuals with a history of LBP describe events that could 
be conceptualized as “recurrent episodes”. The results suggested people with LBP believe 
they live with a baseline level of their condition, and in their opinion, a recurrent episode is 
better represented as a period worsening of their ongoing condition, recognised as “flare-ups” 
 or “attacks”. According to participants’ views, flares were not only characterised by pain, but 
also moderate activity limitations, participation restrictions, need for activities to help 
manage their pain, and fear of worsening of their condition. “Flares” tended to be viewed as 
manageable whereas “attacks” were considered more severe, involving more pain and “the 
inability to do anything”. 
3.2 GROUP B: Validation of a flare definition 
 Twenty-three studies undertook a process to validate the definition or domains of flare 
as summarised in Table 5. All considered rheumatologic conditions (RA – 14; Gout – 1; SLE 
– 6; OA – 2). Only 56% of studies recruited participants from the general community. Others 
used specific groups (30%; e.g. participants receiving a specific treatment) or did not provide 
this information (14%). Of studies aiming to validate a flare definition, 65% (n= 15) were 
observational studies and 21% (n=5) were randomised clinical trials. One study was a 
multicentre trial and one study aimed to validate the flare definition in different languages. 
Disease activity measures were used as the comparator in 65% (n=15) of studies. From those, 
27% (n= 4) used disease activity measures combined with other instruments to measure 
function, health-related quality of life and/or outcome measures of other domains, and 53% 
(n= 8) combined disease activity measures with either patients’ and/or clinicians’ 
perspectives. Eighteen per cent (n=4) relied solely on clinicians’ perspectives, and 9% (n=2) 
considered only patients’ perspectives. In 73% of studies patients and/or investigators were 
blinded to results of the comparator in the validation process. Results are presented below 
separately by condition. 
 
 
 
 Rheumatoid Arthritis 
 Responsiveness of the OMERACT preliminary flare questions (PFQ) to changes in 
flare status determined by rheumatologist, patient self-reported state or one of the two 
proposed DAS28-based criteria was tested. Scores in each PFQ domain changed significantly 
for those experiencing flares and remained unchanged for whose flare status was unchanged. 
DAS28 criteria (Ritchie Articular Index, number of swollen joints, erythrocyte sedimentation 
rate (ESR) and a general health assessment scored on a VAS (40)) were insensitive to change 
(41). Construct and discriminatory validity of the PFQ were examined in a RCT of TNF-
blocking drugs vs. usual care. A statistically significant change in scores (compared to 
baseline) of all PFQ items was found only in patients experiencing a flare defined by DAS28 
(42). Breakout group discussions at OMERACT 2014 identified issues regarding assessment 
of the domains stiffness and self-management. Refinement of RA flare measurement 
continues (43).  Convergent and divergent construct validity of the individual domains of flare 
identified by OMERACT has been assessed (44) from their change over time (3 and 6 
months) and compared against flare defined by DAS28 and three flare working definitions:  
worsening of symptoms (self-reported), change in treatment (observed) and the combination 
of these two domains. Flare defined as ‘self-reported worsening of symptoms’ yielded higher 
standardised mean differences than “change in treatment”.  
 Barlett et al. showed discriminant validity of PFQ between patients with and with 
self-reported flare, and convergent validity between PFQ and validated RA measures (45). 
Bykerk and colleagues showed modest agreement between patients and rheumatologists in 
identifying a flare and the concordance of clinical and patient-reported outcomes (PRO) with 
flare status; patients identifying more swollen and tender joints. PRO significantly 
discriminated between patients reporting flare and those who did not (46) 
   Validity of the FLARE instrument has been assessed in six studies (47-52). First, a 
prospective trial of the FLARE Self-report questionnaire showed it is a valid and valuable 
instrument to detect RA flare between visits to the physician (50). Second, an observational 
study showed good correlation between detection of past flares using the FLARE-RA 
questionnaire and the Routine Assessment of Patient Index Data (RAPID) questionnaire (47). 
Third, comparison of the questionnaire data against clinical and laboratory measures of 
disease activity and severity revealed a high correlation with the all measures except for the 
Physician Clinical Assessment (PCA) (48). Fourth, validity and reliability of the Danish 
version of the Flare Instrument (FI) was found to be excellent against DAS28 (intra class 
correlation coefficient >0.95) (52). Fifth, assessment of the criterion and concurrent validity 
of the Danish version of the FI against DAS28-CRP found good to moderate diagnostic 
properties (49). Sixth, FI was translated into Spanish and a cut-off value ≤50.5 was found to 
determine the presence of a disease flare with high sensitivity and specificity (>60), which 
was more strongly correlated with patient’s opinion and treatment change between visits than 
with physician’s opinion and disease activity scores (51). 
 Two studies validated the definition of flare based on DAS28. Dougados et al. used 
RCT data to compare DAS28 against the investigators’ opinion. DAS 28 was sensitive (88-
100%) but not specific (57-65%) to identification of a flare (53). Portier et al. (54) showed 
difference in conceptualisation of flare between patients and DAS28 (which was considered 
to reflect the physician’s opinion; Kappa 0.44). Patient-reported flares emphasised physical 
and mental domains, but joint pain was rarely indicated as the only flare symptom (16.8% of 
the total flares).  
 
 
 Gout 
 Teoh et al. (55) assessed the validity of six methods to report flare against gout 
disease activity measures [patient and physician global assessments, joint counts and C-
reactive protein (CRP)]. All methods correlated well with measures of gout disease activity, 
except “time to first flare”.     
Systemic Lupus Erythematosus (SLE) 
 Patients with SLE were included in a study examining the intra- and inter-rater 
reliability of the Physician Global Assessment (PGA), the SLEDAI and SELENA. Whereas 
the PGA and the SLEDAI showed high intra- (>0.87) and inter-rater (>0.75) reliability, the 
SELENA tool showed only moderate reliability (<0.52). Agreement among the three 
instruments was poor (56). 
            Data from five visits of 230 SLE patients were assessed to determine correlations 
between SLEDAI scores and clinicians’ views of disease activity levels. A flare was 
considered to have occurred if new or increased therapy was prescribed for active disease, or 
if the physician’s notes indicated an expression of concern or use of the term flare. An 
increase on SLEDAI over 3 points agreed with the clinical determination of flare (26).  
 Isenberg et al. (57) compared flare definitions derived from the BILAG 2004 and the 
SFI against the PGA based on the Lupus Foundation of America (LFA) flare definition. The 
BILAG 2004 based definition of flares was more consistently associated with the opinions of 
physicians. Petri et al. (58) compared the revised SELENA flare index (rSFI) and its original 
version (SFI) to the BILAG index, which discriminates between severe, moderate and mild 
flares in patients with SLE. The results suggest higher agreement between the BILAG and the 
rSFI than its original version (SFI). The SELENA-SLEDAI flare index (cSFI) was compared 
to a version without a criteria related to medication and with clinical judgment. Results 
 indicate that the addition of medication dose did not improve the relationship between cSFI 
and clinically defined flare (59). Brunner et al. (31) identified patients with flare or stable 
jSLE using their candidate flare criteria. PGA, disease activity measure, anti-dsDNA, 
creatinine ratio and parental global assessment of well-being were found to adequately 
capture jSLE global flares diagnosed by rheumatologists. 
Osteoarthritis 
 Using a qualitative methodology Murphy et al. (60) showed that the definition of 
osteoarthritis flare based on “inadequate pain relief brought on by too much activity” did not 
match patients’ perspectives and opinions. Marty et al. (34) revealed good validity for Knee 
Osteoarthritis Flare-Ups Score (KOFUS) and cut-off score to define flare when using the 
rheumatologist diagnosis as a standard. 
4. Discussion  
 This systematic review identified that a process towards a flare definition has been 
initiated for nine of the 12 most burdensome musculoskeletal conditions. Diverse methods 
have been used to derive and/or validate a definition for flare or its domains in 
musculoskeletal conditions with varying degrees of patient consultation. A process to validate 
the definitions/domains has been initiated for only four. For some burdensome diseases (e.g. 
shoulder pain, neck pain and osteomyelitis), no process of definition derivation has been 
initiated. Research in the field of LBP – the most burdensome disease globally in terms of 
years lived with disability (9) – is limited to one qualitative study that indicates people with 
LBP consider their condition to be ongoing and characterised by “flares” rather than discrete 
episodes of pain, even if they have pain-free periods. 
 
 
 4.1 Themes in flare definitions 
 Although several processes to define flare began with an objective to derive a simple 
definition for flare there is consensus that definition requires consideration of multiple 
domains. Pain, impact on function and joint symptoms were the most common themes 
(included in 77% of the definitions). The themes emotional symptoms (55%) and fatigue 
(55%) were frequently considered. Some definitions were uni-dimensional and focused on 
the biomedical features of objective clinical measures (e.g. (5-7)) whereas others were 
multidimensional and considered a biopsychosocial profile with inclusion of objectively 
measured and self-reported aspects of the experience of a flare (e.g. (8, 13)). The methods 
used and groups included in the derivation processes had an impact on the flare definitions. 
As might be expected, when clinicians’ perspectives were emphasised, clinical signs (e.g. 
Gout (19) - pain and warm, swollen and stiff joints) were highlighted. Definitions derived 
using clinicians’ perspectives also tended to exclude “fatigue” as an important component of 
flare, but included “change in treatment” or “pain” as main components (e.g. RA (13, 44)). In 
contrast, consideration of patient perspectives revealed flare as a complex experience and the 
domain “change in treatment” did not adequately identify flares (42, 44, 59). Further, when 
patients’ views were considered, the definitions tended to include a broader biopsychosocial 
conceptualisation of flare, including features such as changes in function, emotional aspects 
and fatigue (e.g. RA, SLE, fibromyalgia and osteoarthritis patients (13, 30, 38, 60)). Not 
surprisingly there is only moderate agreement between patients and physicians regarding 
when they have a flare (37, 41, 54). Regardless of the group considered, there is consensus 
that a definition for flare must consider more than an increase in pain. HCPs’, researchers’ 
and patients’ perspectives appear to be complementary and essential for a deeper 
understanding of flares. This finding agrees with current literature which argues that the use 
of patient reported outcome measures narrows the gap between clinicians’ and patients’ 
 views of health states, leading to better communication and decision making (61). Automated 
methods to identify flare from patient records have not been successful (23, 55) 
4.2 Validation of flare definitions 
 Using a variety of approaches to assess the validity of the proposed 
definitions/domains, most studies showed good relationship with other measures/features of 
flare. Studies relied mainly on comparison against existing clinical measures of disease 
activity and only a few include measures of non-biomedical domains (e.g. fatigue, health 
related quality of life). Thus, in most cases the flare definitions/domains under investigation 
were more multidimensional than the comparators used to validate them. This questions 
whether the studies provide an optimal estimate of validity. Despite this limitation, available 
data show that flare definitions/domains agree with disease activity measures, and correspond 
to patient’s and physician’s perspectives, with some exceptions (48, 60)). An issue to 
consider is that many validation studies relied on participants that are unlikely to represent 
the general population (e.g. limited to a subset of patients receiving a specific intervention).  
4.3 Comparison between conditions 
Among musculoskeletal conditions included in this review, the RA OMERACT 
process towards a flare definition has been the most comprehensive with in-depth 
consideration of all stakeholders’ opinions. Patients have been included in all steps towards a 
flare definition, including perspectives of patients from international sites. Recognising flare 
as a multidimensional construct, the RA OMERACT group were the first to change their 
strategy from derivation of a single phrase to describe the state, to an approach that aims to 
identify the multiple domains that might characterise a flare (6). The established flare 
domains are being used to build a questionnaire to identify flare based on defined thresholds 
(41).  
 No domain was universally used to define a flare among the musculoskeletal 
conditions investigated. The heterogeneity among musculoskeletal conditions, the use of 
different methods and different degrees of maturity of the derivation process to define flare 
makes it difficult to directly compare definitions applied to different conditions. However, 
some differences between flare definitions/domains are clear. First, the complex pathology of 
SLE which affects multiple systems in addition to musculoskeletal issues is reflected in the 
high number and nature of the domains involved in its flare definition. Second, several 
diseases have hallmark signs that are included – e.g. number of swollen/painful joints in RA 
and Gout. Others are less easily identified through clinical signs and do not contain disease-
specific domains - e.g. Fibromyalgia and LBP. 
It might be reasonable to expect that flare in an ongoing systemic condition such as 
RA could be different to conditions commonly characterised by repeated episodes such as 
LBP. However, this was not the case. Contrary to the expectation of Young et al. (39), 
patients with LBP considered their condition to be ongoing (despite periods without pain) and 
characterised by flares rather than discrete symptom episodes.  
Flare in some of the major musculoskeletal conditions have not yet been considered. 
As flare is not considered identically for all conditions, it is not possible to extrapolate from 
existing definitions to conditions where the process has not been commenced and the process 
must be undertaken individually if flare is to be considered an accurate and relevant aspect of 
a condition. It is likely that similar to the other investigated musculoskeletal conditions, flares 
of neck pain, shoulder pain and osteomyelitis may be a multidimensional concept, and 
aspects of the disease and its impact, other than pain, should be considered. 
 
 
 4.4 Flare vs. other types of symptom fluctuation 
This systematic review suggests the concept of flare differs from other definitions 
commonly used to describe fluctuations of symptoms (e.g. episode, recurrence), as those are 
commonly defined only taking into consideration duration, intensity of symptoms, and when 
the period of symptoms is preceded by a period without symptoms (e.g. LBP recurrence 
(62)). It is likely that risk factors for flares will be different to those associated with a new 
episode of a condition, and these need to be studied separately. 
4.5 Conclusion 
The findings of this systematic review indicate that flare is a multifaceted experience 
that differs in some respects between conditions. There is consensus that definitions of flare 
require consideration of aspects in addition to pain and symptom intensity, but the breadth of 
features of the experience of flare was greater when perspectives of patients were considered. 
Whether flare can be adequately defined using a phrase or requires detailed consideration of 
multiple domains has not been established and may vary between conditions. It is clear that 
flare cannot be distilled to a simple consideration of whether treatment has changed. 
Validation of definitions remains challenging as most measures used for comparison are more 
restricted in their consideration of flare that the definitions and domains that have been 
derived. Further work is required to optimise and test the derived definitions for most 
musculoskeletal conditions and work must commence for some.  
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Table 1: Themes used in definition of flare 
Themes Examples 
Worsening of 
condition (WC) 
Worsening of disease activity/condition, a cluster of symptoms, new or 
worse signs, increase in disease activity. 
Change in treatment 
(CT) 
(Re)initiation or change (increase, change medication) of therapy, 
increase/add self-management. 
Pain (P) Pain intensity, nocturnal pain/awakenings, DAS28. 
Symptom intensity 
(SI) 
Intensity of symptoms, overwhelming physical symptoms. 
Duration (D) Duration, persistent, time to maximum pain level, time to complete 
resolution of pain, duration varying between days and weeks. 
Impact on function 
(IF) 
Function, participation, physical symptoms, changes in daily activity, 
Childhood Health Assessment Questionnaire. 
Joint symptoms (JS) Number of joints with active arthritis/limited range of motion, 
swollen/warm/tender/stiff/painful joints, DAS28. 
Patient self-reported 
state (PS) 
Self-reported flare, patient global assessment, parent and patient global 
assessment of overall well-being. 
Biomarkers (B) Laboratory tests (e.g. ESR, CRP levels, acute phase marker). 
Emotional 
symptoms (ES) 
Emotional/psychological changes/symptoms/consequences), health related 
quality of life, coping, anger, depression, withdrawn. 
Physician 
assessment (PA) 
Physician global assessment. 
Fatigue (F) Physical fatigue, emotional fatigue. 
Other (O) Frequent, rare and random, manageable, flu-like symptoms/fever, muscle 
spasm, cramp, burning or tightness in the muscle, sweats, loss of appetite, 
grey pallor, shortness of breath, throughout the entire body. 
 
 
 
 
 
  
 Table 2: Extracted data from derivation studies (Group A) 
Study 
 
  
Process Primary 
purpose 
of study 
Definition or 
domains 
Themes
* 
Measure of 
disease 
activity/sympto
m severity used 
for comparison 
Comments 
Rheumatoid Arthritis (RA) 
RA OMERACT Special Interest Group 
Bingha
m et al.
5 
Literature 
review; 
focus 
groups; 
consensus 
meeting 
Describe 
flare from 
patient’s 
perspectiv
e; identify 
domains 
required 
for 
definition 
A flare 
occurs with 
any 
worsening of 
disease 
activity that 
would, if 
persistent, in 
most cases 
lead to 
initiation or 
change of 
therapy; and 
a flare 
represents a 
cluster of 
symptoms of 
sufficient 
duration and 
intensity to 
require 
initiation, 
change, or 
increase in 
therapy 
WC, D, 
CT, SI 
 
DAS44/DAS2
8 
Two versions 
proposed - 
“change from an 
earlier state” or 
“absolute 
disease activity 
state”. 120 
participants (11 
patients) 
Alten et 
al.
7 
Report from 
OMERACT9 
Report of 
process 
undertaken 
by 
OMERAC
T 
Worsening of 
disease 
activity that 
leads to an 
assessment 
for a change 
in therapy - 
adapted from 
Bingham et 
al.
8
 
WC, 
PA, CT 
 Acknowledge 
patients include 
function and 
participation, 
but not included 
in definition 
Bingha
m et al.
6 
Report from 
OMERACT1
0 
Report 
domains 
identified 
through 
consensus 
Flare 
represents a 
cluster of 
symptoms of 
sufficient 
duration and 
intensity to 
require 
(re)initiation, 
change, or 
increase in 
therapy - 
WC, D, 
SI, CT 
 Change of 
wording to 
“return 
of/(re)initiation”
. 
 adapted from 
Bingham et 
al.
8
 
Hewlett 
et al.
12 
14 Focus 
groups 
across 5 
countries 
Explore 
patient 
perspectiv
e of RA 
flares 
Themes 
highlighted 
by patients: 
Individual 
context, 
uncertainty, 
symptoms 
and early 
warnings, 
self-
management 
of 
intensifying 
symptoms, 
uncontrollabl
e, uncertainty 
and seek help 
when 
symptoms 
cannot be 
contained 
WC, 
CT, SI. 
 Patients report 
current patient 
global VAS 
does not capture 
flare 
 
 Stud
y 
 
 
Proces
s 
Primary 
purpose of 
study 
Definition or domains Them
es* 
Measure of 
disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Bartl
ett et 
al.
8 
Delphi 3 phase 
Delphi to 
determine 
RA flare 
domains 
Consensus achieved in 8 
domains (pain, function, 
swollen joints, tender 
joints, participation, 
stiffness, patient global 
assessment and self-
management) 
 
P, IF, 
J, PS, 
CT 
 Domains for 
development of 
measure of RA flare 
 
 
Byke
rk et 
al.
13
  
Report 
of 
expert 
and 
patient 
consen
sus 
meetin
g 
Endorsemen
t of a core 
domain set 
to measure 
RA flare 
Pain, function, tender 
joints, swollen joints, 
stiffness, patient global 
assessment, participation 
and self-management 
P, IF, 
JS, 
PS, 
CT 
 Laboratory 
values/EGA endorsed 
by HCP (75%), not 
patients. Fatigue - 
endorsed by patients 
(76%), not HCP. 
Domains identified by 
50-70% of patients - 
sleep, systemic 
features and emotional 
distress 
Strategy of treatment in Patients with Rheumatoid Arthritis group of the French Society of Rheumatology 
Berth
elot 
et 
al.
14 
Delphi Build a flare 
questionnair
e based on 
identified 
domains 
Joint swelling, stiffness 
or pain, night pain, 
worsening of condition, 
fatigue, emotional 
consequences, analgesic 
intake, changes in daily 
activity 
JS, 
P,WC, 
F, ES, 
CT, IF 
 Approach 
encompassing any 
disease exacerbation 
(spontaneously 
regressive or long 
lasting), more suitable 
for clinical research 
and daily practice 
Berth
elot 
et 
al.
15 
 
Qualit
ative 
survey 
Assess 
features of 
RA transient 
flares, plus 
physicians'/p
atients' 
attitudes to 
flares 
Joint swelling, stiffness 
or pain, night pain, 
worsening of condition, 
fatigue, emotional 
consequences, analgesic 
intake, changes in daily 
activity 
JS, P, 
WC, 
F, ES, 
CT, IF  
 90% of patients 
considered transient 
flares could induce 
lasting damage, 15% 
anticipated 
rheumatology visit 
 
 Study 
 
 
Proces
s 
Primary 
purpose 
of study 
Definition or domains Theme
s* 
Measure of 
disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Independent research group 
Myasoe
dova et 
al.
16 
Prospe
ctive 
Study 
Establish 
threshold 
for RA 
flare 
using the 
FLARE 
questionn
aire in 
RA 
Flare defined as a score 
of 2.5 or more on The 
Flare Instrument 
JS, P, 
WC, F, 
ES, CT, 
IF 
Th
e 
Fl
are 
ins
tru
me
nt 
 
Juvenile Rheumatoid Arthritis (jRA) 
Brunner 
et al.
17 
RCT Create 
and assess 
candidate 
flare 
criteria 
(1) Worsening in any 2/6 
CRV by ≥40% without 
improvement in more 
than 1 of the remaining 
CRV by ≥30%; (2) 
Worsening in 3 of the 6 
CRV by ≥ 30%; and (3) 
any worsening of the 
Childhood Health 
Assessment 
Questionnaire, 
worsening of ESR by ≥ 
30% and worsening of 
the active joint count by 
≥ 10% 
WC, 
JS, PA, 
PS, B, 
IF 
Co
re 
res
po
ns
e 
va
ria
ble
s 
(C
R
V) 
Placebo treatment 
was criterion standard 
for disease flare – 
patients on placebo 
expected to 
experience flare vs. 
no flare with 
treatment.  
 
Gout 
Taylor 
et al.
21 
Delphi 
proces
s/ 
Cognit
ive 
mappi
ng 
Identify 
domains 
for 
standard 
definition 
of gout 
flare 
Swollen joints, tender 
joints, warm joints, 
patient self-reported of 
pain, patient self-report 
global assessment, time 
to maximum pain level, 
time to complete 
resolution of pain, 
functional status and 
acute-phase marker 
JS, P, 
PS, D, 
IF, B  
  
 
 Study 
 
 
Process Primary 
purpose 
of study 
Definition or domains The
mes* 
Measure 
of disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Gaffo 
et al.
22 
Cohort 
Study 
Develop 
definitions 
for gout 
flare from 
patient-
reported 
features  
(i) Patient-reported 
warm joint, (ii) Patient-
reported swollen 
joint,(iii) Patient-
reported pain at rest 
score of >3 (0–10 scale), 
and (iv) Patient-reported 
flare 
P, 
JS, 
PS 
Rheum
atologis
t 
opinion 
as a 
gold 
standar
d 
Best discrimination – 
3/more of 4 criteria 
(sensitivity 91%, 
specificity 82%). All 4 
criteria provided 
highest specificity 
(96%), PPV (85%) 
MacFa
rlane 
et al.
23
 
Cohort 
study 
Develop/va
lidate a 
claims-
based 
algorithm 
to 
identify 
gout flares 
ICD-9 plus: medication 
claim for any gout-
related 
medications/Colchicine/
NSAID/Cox-2 selective 
inhibitor/oral 
Glucocorticoids/; ICD-9; 
CPT or J code within 7 
days/CPT or J code on 
same day 
CT, 
JS, 
PA 
  
Systemic Lupus Erythematosus (SLE) 
Petri et 
al.
25
 
Cohort 
study 
Investigate 
and 
quantify 
flares 
Change of 0.3 on the 
LAI and a change ≥3 or 
on the SLEDAI 
JS, 
P, 
PS, 
B, 
F, 
O 
 LAI and SLEDAI 
include domains related 
to non-musculoskeletal 
symptoms 
 
 Stud
y 
 
 
Proces
s 
Primary 
purpose of 
study 
Definition or domains The
mes* 
Measure 
of disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Petri 
et 
al.
29
 
RCT Determine 
reliability of 
SELENA 
SLEDAI to 
identify 
flares 
Mild/moderate flare: a 
change in SLEDAI ≥3 
points or new/worse 
skin, stomatitis, serositis, 
arthritis, fever or 
increased prednisone 
<0.5mg/kg/d or added 
NSAID/Plaquenil or ≥1 
increase in a PGA. 
Severe flare: change in 
SLEDAI>12 or 
new/worse CNS-SLE, 
vasculitis, nephritis, 
myositis, Plt<60000 
hemolyticanemia with 
Hb<7mg/dl, requiring 
doubling or > 
0.5mg/kg/d prednisone 
or hospitalization for 
SLE or prednisone 
>0.5mg/kg/d or new 
immunosuppressive or 
increased physician’s 
global assessment to 
>2.5 
JS, P, 
PA, 
CT, 
B, O 
 SLEDAI includes domains 
related to non-
musculoskeletal symptoms 
Glad
man 
et 
al.
26
  
Cohort 
Study 
Determine 
which 
SLEDAI 
score value 
correlate 
with 
clinician 
diagnosis of 
flare 
Increase in SLEDAI of 
>3 
JS, 
PA, 
P, B, 
O 
SL
ED
AI 
SLEDAI includes domains 
related to non-
musculoskeletal 
symptoms. 
 
 Study 
 
 
Process Primary 
purpose 
of study 
Definition or domains The
mes* 
Measure 
of disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Gordo
n et 
al.
28 
Cohort 
study 
Evaluate 
BILAG 
score 
Moderate disease flare can 
be defined as a new B score 
following a C, D, or E score 
according to the BILAG 
index 
JS, P, 
B, F, 
O 
BILAG  
Ehrens
tein et 
al.
27 
Cohort 
Study 
Examine 
occurrenc
e, nature 
and 
distributio
n of flares 
according 
to organ 
involvem
ent 
Change in the BILAG index 
from a score D or E to B, or 
an increase to an A from 
any previous score, 
compared to a previous visit 
in any of eight organs or 
systems 
JS, P, 
B, F, 
O 
BILAG  
Rupert
o et 
al.
30 
Consen
sus 
Panel 
Define 
SLE flare 
Flare is a measurable 
increase in disease activity 
in one or more organ 
systems involving new or 
worse clinical signs and 
symptoms and/or laboratory 
measurements. It must be 
considered clinically 
significant by the assessor 
and usually there would be 
at least consideration of a 
change or an increase in 
treatment 
WC, 
B, 
PA, 
CT 
 Unclear number of 
patients in Consensus 
Panel 
Juvenile Systemic Lupus Erythematosus (jSLE) 
Brunn
er et 
al.
31 
2 
internat
ional 
Delphi 
studies 
Define 
jSLE 
flares 
Flare is a measurable 
worsening of jSLE 
disease activity in at 
least one organ system, 
involving new or worse 
signs of disease that 
may be accompanied 
by new or worse SLE 
symptoms. Depending 
on the severity of the 
flare, more intensive 
therapy may be 
required 
WC, 
SI, 
CT 
 North America (n= 
72), Europe (n= 35), 
Central and South 
America (n=38), Asia 
(n= 5), Africa (n= 3), 
Australia (n= 3). 96% 
consensus reached 
 
 Study 
 
 
Proce
ss 
Primary 
purpose 
of study 
Definition or domains Them
es* 
Measure of 
disease 
activity/sy
mptom 
severity 
used for 
compariso
n 
Comments 
Psoriatic Arthritis (PsA) 
Move
rley 
et 
al.
32 
Qualitati
ve study 
Identify 
patients’ 
perspectives 
of PsA flare 
An overwhelming 
collection of physical, 
psychological and 
emotional symptoms 
SI, IF, 
ES 
 Flare duration  
considered to vary 
from hours-days 
Move
rley 
et 
al.
33 
2 Delphi 
surveys; 
Face-to-
face 
discussio
n 
Develop 
questionnaire 
to determine 
presence of 
flare in PsA 
A change in disease 
state that necessitates a 
change in treatment or 
as a marked worsening 
of ability to continue 
with activities of daily 
living.” Domains: 
Articular, skin, 
emotional, participation 
and fatigue 
CT, 
WC, 
IF, JS, 
ES, F 
 “Flare” - short-lived 
and acute; 
“worsening of 
disease” - slower and 
longer-lived 
 
 
Osteoarthritis (OA) 
Mart
y et 
al.
34 
Observati
onal 
cross-
sectional 
Derive and 
validate a 
definition of 
flare in OA 
A cut-off of 7 on the 
KOFUS scale 
JS, D, 
P, IF 
 
KOFUS Scale  
 
 Study 
 
 
Process Primary 
purpose 
of study 
Definition or 
domains 
Themes* Measure of 
disease 
activity/symptom 
severity used for 
comparison 
Comments 
Ankylosing Spondylitis (AS) 
Brophy 
and 
Calin
35 
Group 
Meetings  
Examine 
patient’s 
perception 
of factors 
important 
in defining 
flare 
 (1) Localized 
to one area: 
frequent, 
duration 
varying 
between days 
and weeks, 
acute and 
sudden pain in 
one area, 
which may 
move to other 
area. 
Occasional 
swelling, 
inability to 
move joint, 
immobility, 
fatigue, bad 
temper, 
withdrawn. 
Attitude: adapt 
and learn to 
live with it.  
(2) Throughout 
the entire 
body: Rare and 
random, 
duration 
varying 
between days 
and weeks, 
paralysing and 
throbbing pain 
inside and in 
every joint. 
Immobility, 
fatigue, muscle 
spasm, cramp, 
burning or 
tightness in the 
muscle. 
Sweats, fever, 
flu-like illness, 
loss of 
appetite, grey 
pallor, 
shortness of 
breath, 
D, P, JS, 
IF, F, ES, 
O 
 
  
 depression, 
anger. 
Attitude: 
devastating 
every time. 
Assessment of Spondyloarthritis (ASAS) group 
Gossec 
et al.
36
 
Systematic 
literature 
review, 
Vignette 
exercises 
Develop 
definition 
for 
“flare” 
based on 
validated 
composite 
indices 
Candidate flare 
definitions: Δ 
pain ≥2 + final 
value ≥4; Δ 
pain ≥3; If 
observed value 
is ≥4: Δ pain 
≥2 points, 
otherwise: Δ 
pain ≥3 points; 
Δ BASDAI ≥2 
points; Δ 
BASDAI ≥2 
points + final 
value ≥4; Δ 
BASDAI ≥3 
points; Δ 
BASDAI ≥3 
points + final 
value ≥4; If 
observed value 
is ≥4, Δ 
BASDAI ≥2 
points, 
otherwise: Δ 
BASDAI ≥3 
points; Δ 
ASDAS ≥0.6; 
Δ ASDAS 
≥0.9; Δ 
ASDAS ≥1.1; 
Δ ASDAS 
≥0.6 + 
observed 
ASDAS ≥1.3 
P, JS, PS, 
F, B  
ASDAS, 
BASDAI 
 
 
 
 Study 
 
 
Process Primary 
purpose of 
study 
Definition 
or domains 
Themes
* 
Measure of 
disease 
activity/sympto
m severity used 
for comparison 
Comment
s 
Godfrin
-Valnet 
et al.
37 
Longitudina
l study 
Evaluate 
thresholds 
of disease 
activity 
variations 
using 
validated 
instruments 
Variation of 
≥2.1 in 
BASDAI, 
0.8 units in 
ASDAS-
ESR and 
1.3 in 
ASDAS-
CRP 
P, JS, 
PS, F, 
B 
  
Fibromyalgia 
Vincent 
et al.
38 
Qualitative 
Study 
Describe 
flares in 
patients 
with 
fibromyalgi
a 
Pain, flu-
like 
symptoms, 
fatigue and 
emotional 
symptoms 
P, ES, 
F, O 
 Patients 
argued 
flares 
differed 
from 
everyday 
symptoms 
by being 
larger and 
more 
intense 
than usual, 
to the point 
where it 
feels 
disabling 
Low back pain (LBP) 
Young 
et al.
39 
Qualitative 
Study 
Investigate 
patients’ 
perspectives 
of recurrent 
LBP 
episodes 
An 
increased 
experience 
of pain, but 
not too 
intense – 
causing 
some 
additional 
activity 
limitations 
and 
participatio
n 
restrictions, 
but 
manageable 
P, SI, 
IF, O 
  
DAS44/DAS28 – Disease Activity Score. The numbers 44 and 28 refers to the 44/28 joints that are examined in this instrument; VAS - 
Visual Analogue Scale; EGA - Evaluator Global Assessment; HCP – Health Care Professionals; RCT – Randomized controlled trial; CRV – 
Core Response Variables; PGA – Physician’s Global Assessment; ESR – Erythrocyte Sedimentation Rate; ICD-9 – International 
Classification of Disease-9; NSAID - Nonsteroidal Anti-Inflammatory Drugs; CPT – Current Procedural Terminology; J code - Healthcare 
Common Procedure Coding System (HCPCS) codes for injection of drugs; LAI – Lupus Activity Index; SLEDAI - Systemic Lupus 
Erythematosus Disease Activity Index; SELENA Flare tool - Safety of Estrogens in Lupus Erythematosus National Assessment  Flare tool; 
CNS-SLE – Central Nervous System-Systemic Lupus Erythematosus; PLT - Platelet; HB - Haemoglobin; BILAG - British Isles Lupus 
Assessment Group 2004 index; KOFUS – Knee Osteoarthritis Flare-ups Score; ASDAS - Ankylosing Spondylitis Disease Activity Score; 
 ASDAS-CRP – Ankylosing Spondylitis Disease Activity Score-C-reactive protein; ASDAS-ESR - Ankylosing Spondylitis Disease Activity 
Score-Erythrocyte Sedimentation Rate; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.  
* See Table 1 for abbreviations for Themes 
 
Table 3: Extracted data from validation studies (Group B) 
Study Sample 
characteristics 
Validation 
method d 
Definition/domain 
investigated 
Comparator 
for Validation 
Outcomes of 
validation 
Rheumatoid Arthritis (RA) 
RA OMERACT Special Interest Group 
Bykerk 
et al.
41 
N=501, 
observational 
cohort study 
Longitudinal 
Observational 
Study  
PFQ Rheumatologist 
diagnosis of 
flare, patient 
self-reported 
flare, and 2 
proposed 
DAS28-based 
criteria  
PFQ domain 
scores changed 
with flare status 
of patients and 
remained stable 
in patients with 
unchanged flare 
status. Inter-
rater reliability - 
flare status of 
rheumatologist 
vs. patient - 
74% (Kappa 
0.34); lower 
with most 
specific DAS 
criterion - 72% 
(Kappa 0.17) 
Van 
Der 
Maas 
et al.
42 
N=180, treated 
with usual care 
or TNF-
blockers for 6 
months, 
DAS28<3.2, 
RA treatment 
>6 months 
Randomized 
Controlled 
Trial 
PFQ DAS28 Scores for each 
PFQ domain 
unchanged in 
patients without 
flare, change 
across all PFQ 
items in those 
with flare 
defined by 
DAS28 
Bartlett 
et al.
43 
N/A Report of 
OMERACT 
2014 RA 
Flare Group 
and breakout 
groups 
N/A N/A Breakout 
groups - 
morning 
stiffness 
duration may 
not capture 
patients’ 
experiences; 
insufficient 
scope of self-
management 
activities 
 
 
 Study
 
Sample 
characteristic
s 
Validation 
method d 
Definition/domai
n investigated 
 
Comparator 
for Validation 
Outcomes of 
validation 
Lie et 
al.
44
 
N=1195, 
taking 
DMARDS 
Longitudinal 
Observational 
Study: Validity 
of domains 
assessed using 
logistic 
regression 
analysis  
Validation 1: 
“Domains of flare” 
identified by 28-
SJC; 28 TJC; ESR, 
CRP, VAS for 
pain, fatigue and 
PGA
1
, SF-36, 
MHAQ score, 
morning stiffness 
intensity and 
duration 
(BASDAI).  
Validation 2:  
Patient self-
reported 
worsening, 
treatment change 
DAS28 + three 
working 
definitions: 
patient self-
reported 
worsening, 
treatment 
change, or both 
self-reported 
worsening and 
treatment 
change 
DAS28 
“Domains of 
flare” more 
strongly 
correlated with 
“self-reported 
worsening of 
symptoms” than 
“change in 
treatment”. 
“Domains of” 
flare were 
related to 
DAS28 
 
DAS28 more 
related to 
“patient self-
reported 
worsening” 
than “change in 
treatment”.  
Bartlet
t et 
al.
45 
N=1190, from 
Canadian early 
Arthritis 
CoHort 
(CATCH) 
Cohort Study: 
Discriminant 
validity of 
PFQs, 
convergent 
validity among 
PFQs and 
validated RA 
measures 
PFQs HAQ, SF12, 
RADAI, WPAI 
and Patient 
Global 
Agreement 
among single 
item PFQs and 
validated RA 
measures. PFQ 
scores higher 
across domains 
for patients 
reporting flares 
Bykerk 
et al.
46 
N=512, 
CATCH 
Cohort Study: 
Agreement 
between 
patients and 
rheumatologist
s  
Pain, function, 
stiffness, 
participation, 
coping, patient 
global assessment, 
fatigue and self-
management 
according to 
patients 
Pain, function, 
stiffness, 
participation, 
coping, patient 
global 
assessment, 
fatigue and 
self-
management 
according to 
rheumatologist
s 
Modest 
agreement - 
patients vs. 
rheumatologists
. Pain, function, 
stiffness, 
coping, 
participation, 
fatigue 
discriminate 
patients with vs. 
without flare 
 
 
 Study Sample 
characteristic
s 
Validation 
method d 
Definition/domai
n investigated 
Comparato
r for 
Validation 
Outcomes of 
validation 
Strategy of treatment in Patients with Rheumatoid Arthritis group of the French Society of 
Rheumatology 
Fautrel et 
al.
50 
N=138, ≥18 
years, 
(1987 ACR 
and/or 2010 
ACR/EULAR  
Prospective 
Study 
FLARE-RA self-
administered 
questionnaire* 
RAPID-3, 
RAID, 
DAS28 and 
HAQ
 
Good content 
and construct 
validity of 
FLARE-RA. 
Floor effect, 
no ceiling 
effect. 
FLARE-RA 
total score 
correlated 
with DAS28 
(r=50.63, 
P<0.001), 
RAID 
(r=50.80, 
P<0.001), 
RAPID-3 
(r=50.77, 
P<0.001), and 
HAQ 
(r=50.53, 
P<0.001). 
ICC(reliability
) - 0.94 (95% 
CI 0.92–0.96) 
Morel et 
al.
47 
N=132, 13 
centres (1987 
ACR criteria, 
duration >6 
months), 
treated 
DMARDs 
Prospective 
Study 
FLARE-RA 
questionnaire* 
RAPID3 
self-
administere
d 
questionnair
e 
FLARE-RA 
questionnaire 
detected past 
flares defined 
by RAPID3 
Myasoedov
a et al.
48
  
N=160 (1987 
ACR criteria) 
Cohort Study: 
Correlation - 
FLARE 
questionnaire vs. 
clinical/laborator
y measures  
FLARE 
questionnaire* 
BRAF, 
HAQ, VAS 
pain, CRP, 
IL6, PCA, 
PGA
1 
FLARE 
score/subscale
s correlated 
with all 
comparators, 
except PCA 
CRP 
correlated 
with overall 
score and 
systemic 
subscale 
 
 Study Sample 
characteristics 
Validation 
method d 
Definition/domain 
investigated 
Comparator 
for 
Validation 
Outcomes of 
validation 
de Thurah 
et al.
49 
N=117, (ACR 
1987/2010 
criteria), 
visiting 
outpatient 
clinic, treated 
with DMARDs 
Cohort 
Study: ROC 
curves, 
sensitivity, 
specificity, 
PPV and 
NPV, 
likelihood 
ratio and 
Spearman 
correlation 
coefficient 
Danish version of 
Flare instrument 
(FI) 
 
DAS28-CPR 
(criterion 
standard), 
HAQ and 
CRP 
(concurrent 
validity) 
 
 
Sensitivity 
(detect flare 
identified by 
DAS28) - 
85.4% (95% CI, 
72.2; 93.9); 
specificity - 
50.7% (95% CI, 
38.4; 63.0). 
PPV - 53.6% 
(95% CI, 47.0; 
60.1) NPV - 
83.9% (95% CI, 
7; 91.5). AUC - 
~77%. 
Moderate 
correlation 
DAS28-CPR 
vs. FI, poor 
correlation CRP 
vs. FI and FI vs. 
HAQ 
Maribo et 
al.
52 
N=117, Dutch 
patients (ACR 
1987/2010 
criteria) visiting 
outpatient 
clinic, treated 
with DMARDs 
Cross-
cultural 
Study: 
Forward 
and back-
ward 
translation 
and 
calculation 
of LOA, 
SEM, MDC 
and ICC.  
Flare instrument* DAS28 Instrument 
identifies >80% 
RA patients 
without flare 
Lizarraga 
A et al. 
51 
N=105, ≥18 
years 
(ACR/EULAR 
2010 criteria) 
Translation 
and cultural 
adaptation  
FLARE 
Questionnaire 
DAS28, 
RAPID, 
patient’s 
opinion and 
physician’s 
opinion 
FLARE 
questionnaire 
validated for 
detecting RA 
disease flare 
Dougados 
et al.
53 
N=553 from a 
RCT 
Post hoc 
analysis of 
RCT 
Increase in DAS28, 
between 2 visits, of 
>1.2 or >0.6 if the 
current DAS28 
≥3.2 
Worsening of 
disease 
activity which 
required 
increased 
treatment 
beyond 
permitted 
supportive 
therapy 
DAS28-2 - 
sensitive (88–
100%), poor 
specificity (57–
65%), for 
detecting flare 
 
 Study Sample 
characteristic
s 
Validation 
method d 
Definition/domai
n investigated 
Comparato
r for 
Validation 
Outcomes of 
validation 
Portier et 
al.
54 
N=134, ≥18 
years (ACR 
1987 criteria) 
Post-hoc 
analysis of 
Randomize
d 
Controlled 
Trial 
Increase of 
DAS28>0.6 and an 
absolute value of 
DAS28>2.6 
(physician 
assessment) 
Patient-
reported 
flares 
Flare concept 
differs between 
patients and 
physicians 
(Kappa 0.44). 
Patients consider 
flare is more 
than disease 
activity 
Gout 
Teoh et al.
55 
N=120 from 
RCT 
Randomize
d 
Controlled 
Trial: 
Correlation 
between 
flare 
reporting 
and 
measures of 
gout 
activity 
Pain score >3, 
patient self-report 
flare (SRF), flare 
count, time to first 
flare, number of 
days with (SRF) 
and (SRF) 
requiring 
medication  
Area under 
curve (AUC) 
variable time 
plot analysis, 
patient and 
physician 
global 
assessments, 
joint counts, 
and CRP 
Flare reporting 
flare correlated 
with measures of 
disease severity, 
except time to 
first flare 
Systemic Lupus Erythematosus (SLE) 
FitzGerald 
and 
Grossman.
5
6 
N=22 - intra-
rater 
reliability; 
N=26 inter-
rater reliability 
Cohort 
Study: 
Validity, 
intra- and 
inter-rater 
reliability 
between 
two 
physicians 
abstracting 
PGA
2
, 
SLEDAI 
and 
SELENA 
flare tool 
Flare defined by 
PGA
2
, SLEDAI 
and SELENA 
Flare tool 
Flare defined 
by PGA
2
, 
SLEDAI and 
SELENA 
Flare tool 
Poor agreement 
flares definitions 
among 
instruments. 
Poor validity of 
timing of flare at 
a specific 
patient-level. 
Flare better 
assessed over 
specific time 
period 
 
Gladman et 
al.
26 
N=230  Cohort 
Study: 
Descriptive 
statistics 
identified 
SLEDAI 
score = flare 
defined by 
physicians 
SLEDAI scores Physicians’ 
impression 
of disease 
activity (new 
or increased 
therapy for 
activity 
disease, 
expression 
of concern, 
use of 
“flare” in 
notes) 
Increased 
SLEDAI >3 = 
flare identified 
by physician. 
Improvement - 
reduced 
SLEDAI >3; 
persistently 
active disease - 
increase/decreas
e of SLEDAI up 
to 3; remission - 
SLEDAI = 0 
 
 Study Sample 
characteristics 
Validation 
method d 
Definition/domain 
investigated 
Comparator 
for 
Validation 
Outcomes of 
validation 
Isenberg 
et al.
57 
N=16 Cohort Study: 
Assessment of 
internal 
reliability of 3 
instruments 
(ICC with 95% 
CI) 
BILAG 2004, 
SELENA Flare and 
PGA
2 
(LFA Flare 
definition used by 
16 assessors) 
BILAG 
2004, 
SELENA 
Flare and 
PGA
2
 (LFA 
Flare 
definition 
used by 16 
assessors) 
BILAG 2004 
defined flares 
performed 
better [ICC 
(95% CI) at 
0.54 (0.32 to 
0.78)] than 
SELENA flare 
[at 0.21 (0.08 
to 0.48)] and 
PGA
2
 tools 
[0.18 (0.06 to 
0.45)] 
Petri et 
al.
58 
N=235, 
moderate to 
severe disease 
activity using 
rontalizumab 
(anti-interferon 
alpha) 
Randomized 
Controlled 
Trial: rSFI vs. 
SFI and BILAG 
flare index. 
Inter instrument 
agreement - 
Cohen’s 
kappa/weighted 
kappa 
coefficient  
rSFI SFI, BILAG 
flare index 
Substantial 
agreement 
between rSFI 
and SFI. 
BILAG flare 
index - better 
agreement 
with rSFI than 
SFI 
 
Thanou 
et al.
59 
N=91 (1997 
modified ACR  
criteria for 
SLE) 
Cohort Study: 
cSFI and eSFI 
were compared. 
Descriptive 
statistics used to 
describe 
measures of 
disease activity 
and flare 
cSFI (includes 
medication)  
eSFI 
(excludes 
medication), 
SLEDAI, 
BILAG, 
PGA
2 
eSFI better 
than cSFI  
eSFI- 
improves 
discrimination 
of mild vs. 
moderate 
flares, selects 
more ill 
patients with 
clinical 
worsening for 
each category 
of flare 
Medication - 
not distinguish 
the severity of 
a clinical flare 
 
 Study Sample 
characteristics 
Validation 
method d 
Definition/domain 
investigated 
 
Comparator 
for Validation 
Outcomes 
of 
validation 
Juvenile Lupus Erythematosus Systemic (jSLE) 
Brunner 
et al.
31 
98 Children 
with jSLE, ≤16 
years 
Multicentre 
Study 
A flare is a 
measurable 
worsening of juvenile 
SLE disease activity 
in at least one organ 
system, involving 
new or worse signs of 
disease that may be 
accompanied by new 
or worse SLE 
symptoms. 
Depending on the 
severity of the flare, 
more intensive 
therapy may be 
required 
Rate change in 
the jSLE course 
by paediatric 
rheumatologist 
(10+ year 
experience) 
jSLE flares 
determined 
by 
Physician-
rated disease 
activity, 
disease 
activity 
index score, 
health 
related 
quality of 
life  
Osteoarthritis (OA) 
Murphy 
et al.
60 
Symptomatic 
knee OA 
(n=45) 
Cohort Study: 
% patient’s 
agreement 
with 
investigator’s 
flare 
definition  
Inadequate pain relief 
for an episode of 
intense pain that is 
usually brought on by 
too much activity 
Patients’ 
definition 
~50% 
participants 
- definition 
did not 
match 
personal 
definition. 
11% 
participants 
“very much” 
agreed  
Marty 
et al.
34 
641 patients 
(285 – flare,  
356 – stable 
condition) 
CS: 
Sensitivity, 
specificity, 
PPV and 
NPV 
KOFUS (cut-off 
score=7) 
Rheumatologist 
diagnosis 
Sensitivity - 
87.0%, 
specificity - 
87.9%, PPV 
85.8%, NPV 
89.0% 
PFQ – Preliminary Flare Questionnaire; DAS/DAS28 – Disease Activity Score. The number 28 refers to the 28 joints that are examined in 
this instrument; DAS28-CRP - A composite score including the patient’s global assessment, report of physical functioning (HAQ), and the 
measurement of an acute phase reactant (CRP), together with a physician-based count of tender and swollen joints; N/A – Not applicable; 
DMARDS – Disease Modifying Anti-rheumatic Drugs; 28-SJC – 28-Swollen Joint Counts; 28-TJC – 28-Tender Joint Counts; ESR – 
Erythrocyte Sedimentation Rate; CRP – C-reactive protein; VAS - Visual Analogue Scale; PGA1 - Patient Global Assessment; SF36 – 36-
item short form survey (SF36 Bodily pain, SF36 Physical functioning, SF36 Social functioning, SF36 Role limitations physical, SF36 Role 
limitations emotional, SF36 Mental health); MHAQ – Modified Health Assessment Questionnaire; BASDAI – Bath Ankylosing Spondylitis 
Disease Activity Index; HAQ - Health Assessment Questionnaire; SF12 – Short Form 12 Questionnaire; ACR criteria – American College 
of Rheumatology criteria; RAID - Rheumatoid Arthritis Impact of Disease; RAPID - Routine Assessment of Patient Index Data; RAPID3 – 
Routine Assessment of Patient Index Data 3; BRAF - Bristol Rheumatoid Arthritis Fatigue; ICC – Intra-class Correlation Coefficients; IL6 - 
Interleukin-6; ROC – Receiver Operating Characteristic; PPV – Positive Predictive Value; NPV – Negative Predictive Value; PCA - 
Physician Clinical Assessment; SEM – Standard Error of the Measurement; Work productivity and Activity Impairment Questionnaire – 
WPAI; LOA – Limits of Agreement; MDC – Minimally Detectable Change; PGA2 – Physician’s Global Assessment; LFA – Lupus 
Foundation of America; SLEDAI - Systemic Lupus Erythematosus Disease Activity Index; SELENA Flare tool - Safety of Estrogens in 
Lupus Erythematosus National Assessment  Flare tool; BILAG - British Isles Lupus Assessment Group 2004 index; SFI - Selena Flare 
Index; rSFI – Revised Selena Flare Index; eSFI – Experimental Selena Flare Index; cSFI – Classic Selena Flare Index; jSLE – Juvenile 
Systemic Lupus Erythematosus; OA – Osteoarthritis; KOFUS – Knee Osteoarthritis Flare-ups Score.  
* Flare self-reported questionnaire, Flare-RA questionnaire, Flare assessment in RA (FLARE) questionnaire and Flare Instrument (FI): all 
refer to the same instrument. 
 
  
 Table 4: Assessment of quality of derivation process 
Study Clear 
identificat
ion of 
condition 
Perspecti
ve: 
Patient 
Perspectiv
e: 
Clinician 
Perspectiv
e: 
Experts 
Derivation 
Process* 
Used a 
research 
method to 
identify a 
threshold/c
ut-off for 
flare 
Consens
us 
Process 
Rheumatoid Arthritis (RA) 
RA OMERACT Special Interest Group 
Bingham 
et al.
5 
Yes Yes Yes Yes LR, F, CM, 
W 
No Yes 
Alten et 
al.
7 
Yes N/A N/A N/A Q, RCT, L No Yes 
Bingham 
et al.
6 
Yes N/A N/A N/A Q, F, D, 
LR, RCT, B 
No Yes 
Hewlett et 
al.
12 
Yes Yes No No F No Yes 
Bartlett et 
al.
8 
Yes Yes Yes Yes D No Yes 
Bykerk et 
al.
13 
Yes Yes Yes Yes CM No Yes 
Strategy of treatment in Patients with Rheumatoid Arthritis group of the French Society of 
Rheumatology 
Berthelot 
et al.
14 
Yes Yes Yes Yes Q, D No Yes 
Berthelot 
et al.
15 
Yes Yes Yes No Q No Yes 
Independent research group 
Myasoedo
va et al.
16 
Yes Yes Yes No P Yes No 
Juvenile Rheumatoid Arthritis (jRA) 
Brunner et 
al.
17 
Yes No Yes No RCT Yes No 
Gout 
Taylor et 
al.
21 
Yes Yes Yes Yes D No Yes 
Gaffo et 
al.
22 
Yes Yes Yes Yes C No No 
MacFarlan
e et al.
23 
Yes No Yes No C No No 
Systemic Lupus Erythematosus (SLE) 
Petri et 
al.
25 
Yes No Yes No C No No 
Petri et 
al.
29 
Yes No Yes No RCT Yes No 
Gladman 
et al.
26 
Yes No Yes No C Yes No 
Gordon et 
al.
28 
Yes No Yes No C Yes No 
Ehrenstein 
et al.
27 
Yes No Yes No C No No 
Ruperto et 
al.
30 
Yes Yes Yes Yes CP No Yes 
Study Clear Perspecti Perspecti Perspecti Derivat Used a Consen
 identification of 
condition 
ve: 
Patient 
ve: 
Clinician 
ve: 
Experts 
ion 
Process
* 
research 
method to 
identify a 
threshold/cut
-off for flare 
sus 
Process 
Juvenile Lupus Erythematosus Systemic (jSLE) 
Brunne
r et 
al.
31 
Yes No Yes No D No Yes 
Psoriatic Arthritis (PsA) 
Moverl
ey et 
al.
32 
Yes Yes No No Q No No 
Moverl
ey et 
al.
33 
Yes Yes Yes No D, B No Yes 
Osteoarthritis (OA) 
Marty 
et al.
34 
Yes Yes Yes No OCS Yes No 
Ankylosing Spondylitis (AS) 
Brophy 
and 
Calin
35 
Yes Yes No No GM No No 
Assessment of Spondyloarthritis (ASAS) group 
Gossec 
et al.
36 
Yes No Yes Yes LR, V No No 
Godfri
n-
Valnet 
et al.
37 
Yes Yes Yes No L Yes No 
Fibromyalgia 
Vincen
t et 
al.
38 
Yes Yes No No Q No No 
Low back pain (LBP) 
Young 
et al.
39 
Yes Yes No No Q No No 
LR – Literature review; F – Focus group; CM – Consensus Meeting; W – Workshop;  Q – Qualitative Study; RCT – Randomised Controlled 
Trial; D – Delphi; B – Breakout groups; P – Prospective Study; C – Cohort study; CP – Consensus Panel; OCS – Observational cross-
sectional study; GM – Group meetings; V – Vignette exercise; L – Longitudinal study. 
*All definitions derived comprised multiple domains. 
 
 
 
 
 
 
 
  
 Table 5: Assessment of quality of validation process 
Study Clear 
identification 
of condition 
Representative sample Clear 
description 
of 
comparator 
Blinding of 
patients 
and 
clinicians 
to results 
of the 
comparator 
Inclusion 
of 
follow-up 
Rheumatoid Arthritis (RA)  
RA OMERACT Special Interest Group 
Bykerk et 
al.
41 
Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 
Yes Unclear Yes 
Van Der 
Maas et al.
42 
Yes RCT using TNF-blockers or 
usual care 
Yes Yes Yes 
Bartlett et 
al.
43
  
Yes N/A N/A N/A N/A 
Lie et al.
44 
Yes 5 Norwegian rheumatology 
departments using DMARDS 
and/or biologics.  
Yes Yes Yes 
Bartlett et 
al.
45
  
Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 
Yes Yes Yes 
Bykerk et 
al.
46 
Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 
Yes Yes Yes 
Strategy of treatment in Patients with Rheumatoid Arthritis group of the French Society of 
Rheumatology 
Fautrel et 
al.
50 
Yes 138 patients >18 years with 
RA diagnosis (1987 ACR 
and/or 2010 ACR/EULAR 
criteria), disease evolving for 
≥6 months, treatment with 
synthetic or biologic 
DMARDS for ≥2 months and 
stable symptomatic treatment 
for ≥2months  
Yes Yes Yes 
Morel et 
al.
47 
Yes Patients from 13 treated with 
stable doses of DMARDs 
Yes Yes Yes 
Myasoedova 
et al.
48 
Yes 160 RA Patients - 
population-based cohort 
(1987 ACR criteria) 
Yes Yes Yes 
de Thurah et 
al.
49 
Yes Outpatient clinic treated with 
DMARDs 
Yes N/A N/A 
Maribo et 
al.
52 
Yes Out-patient clinic in 
Denmark 
Yes N/A N/A 
Lizarraga A 
et al.
51 
Yes ≥18 years, RA 
(ACR/EULAR 2010 criteria) 
Yes Yes Yes 
 
 Study Clear 
identification 
of condition 
Representative 
sample 
Clear 
description 
of 
comparator 
Blinding of 
patients and 
clinicians to 
results of the 
comparator 
Inclusion 
of follow-
up 
Independent Research Groups 
Dougados et 
al.
53 
Yes 553 patients, 118 
centres in 19 
countries (Europe, 
America and Asia) 
using tocilizumab + 
methotrexate or 
placebo 
Yes Yes Yes 
Portier et 
al.
54 
Yes ≥18 years, RA (ACR 
1987 criteria) 
Yes Yes Yes 
Gout 
Teoh et al.
55 
Yes 120 gout patients Yes Yes Yes 
Systemic Lupus Erythematosus (SLE) 
FitzGerald 
and 
Grossman
56 
Yes Randomly selected 
from rheumatology 
outpatient clinics 
(UCLA – Los 
Angeles) 
Yes Yes Yes 
Gladman et 
al.
26 
Yes Patients from Uni. 
Toronto Lupus Clinic 
No Yes Yes 
Isenberg et 
al.
57
  
Yes Limited to patients 
from 2 lupus clinics 
seeking care during 
the previous 3 weeks 
Yes Yes No 
Petri et al.
58 
Yes Limited to patients 
from a RCT 
conducted in USA, 
Latin America and 
Europe using 
rontalizumab 
Yes Yes Yes 
Thanou et 
al.
59 
Yes Limited to SLE 
patients - Oklahoma 
Lupus Cohort Study, 
(1997 modified ACR 
criteria) 
Yes No Yes 
Brunner et 
al.
31 
Yes Limited to patients 
≤16 years from 7 US 
paediatric 
rheumatology clinics  
No Yes Yes 
Osteoarthritis (OA) 
Murphy et 
al.
60 
Yes Limited to  moderate 
to severe pain from 
the Uni. Michigan 
Clinics 
No No Yes 
Marty et 
al.
34 
Yes Clinical and 
radiological criteria 
for knee osteoarthritis 
(ACR) 
No Yes No 
RCT – Randomized Controlled Trial; DMARDS – Disease Modifying Anti-rheumatic Drugs; ACR– American College of Rheumatology; 
EULAR - European League Against Rheumatism.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified 
through database 
searching  
(n = 6,895) 
S
cr
ee
n
in
g
 
In
cl
u
d
ed
 
E
li
g
ib
il
it
y
 
Id
en
ti
fi
ca
ti
o
n
 Additional records 
identified through 
other sources  
(n = 2) 
Records after duplicates removed  
(n = 3,989) 
Records screened  
(n = 3,989) 
Records excluded  
(n = 2,449) 
‘Flare’ not defined (n=1993) 
Pregnant women (n=320) 
Animal studies (n=53) 
Participants undergoing surgery (n=46) 
Induced flares (n=19) 
Non-musculoskeletal conditions (n=18) 
Full-text articles assessed 
for eligibility  
(n = 1,540) 
Full-text articles excluded  
(n = 1,489) 
“Flare” not defined (n=829) 
flare definition/domains not derived or 
validated (n=397) 
Study did not derive or validate a “flare” 
definition (n= 263) 
Studies included in 
qualitative synthesis  
(n = 51) 
Studies reporting 
derivation of flare 
definition 
(n = 28) 
Studies reporting 
validation of flare 
definition 
(n = 23) 
F
ig
u
re
 2
. 
N
u
m
b
er
 o
f 
co
n
d
it
io
n
s 
(o
u
t 
o
f 
9
 m
aj
o
r 
co
n
d
it
io
n
s)
 t
h
at
 i
n
cl
u
d
ed
 c
o
n
si
d
er
at
io
n
 o
f 
ea
ch
 t
h
em
e 
in
 t
h
e 
fl
ar
e 
d
ef
in
it
io
n
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 3
. 
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u
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b
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th
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o
n
si
d
er
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 f
o
r 
ea
ch
 c
o
n
d
it
io
n
 (
o
u
t 
o
f 
1
3
 t
h
em
es
).
 
 
